MSC Secretome
The complete cellular output of soluble proteins, lipids, metabolites, extracellular vesicles and other released biological material.
CELLMEX Scientific Library
MSC Secretome
The MSC secretome is the complete collection of soluble and vesicular biological material released by mesenchymal stromal cells into their surrounding environment. It includes cytokines, chemokines, growth factors, proteins, metabolites, lipids and extracellular vesicles.
Scientific Definition
What exactly is the MSC secretome?
Mesenchymal stromal cells continuously release biological signals into the environment surrounding them. The collective output of this cellular secretion is known as the MSC secretome.
The secretome contains both freely soluble molecules and membrane-enclosed extracellular vesicles. It is therefore broader than purified exosomes, small extracellular vesicles or an isolated protein preparation.
In practical laboratory work, the secretome is commonly recovered through conditioned medium. That collected medium may then be clarified, concentrated, fractionated, purified or formulated according to the intended research or product objective.
MSC-Conditioned Medium
The culture medium collected after MSCs have released secretome components into the surrounding liquid environment.
Secretome-Derived Product
A processed preparation produced by concentrating, fractionating, purifying or formulating selected components of the MSC secretome.
Secretome Biology
A dynamic system of intercellular communication
MSC-secretome activity is principally associated with paracrine signalling rather than direct replacement of damaged tissue by the source cells.
Paracrine Signalling
MSC-derived factors may influence nearby or distant recipient cells without requiring the source cells to become permanently incorporated into the tissue.
Immunomodulation
Cytokines, chemokines, proteins and vesicles may influence macrophages, lymphocytes, dendritic cells and other immune-cell populations.
Trophic Support
Secreted factors are studied for their potential to support cellular survival, stress resistance, migration and endogenous repair responses.
Vascular Signalling
Selected secretome components may influence endothelial-cell activity, angiogenic pathways and microvascular support in experimental systems.
Matrix Regulation
Proteins and enzymes may affect extracellular-matrix synthesis, degradation, fibrosis-related signalling and tissue remodelling.
Extracellular-Vesicle Communication
Secretome-associated vesicles may interact with recipient-cell membranes and carry proteins, lipids, RNA and other molecular material.
Laboratory Production
How the MSC secretome is produced
The secretome is not differentiated. The MSC source cells may be expanded, primed or lineage-directed; their released biological output is then collected and processed.
Source-Cell Qualification
Define the MSC tissue source, donor, immunophenotype, passage number, viability and culture history.
Controlled MSC Expansion
Expand cells under documented culture-medium, supplement, confluence, oxygen and environmental conditions.
Optional Priming or Preconditioning
Where scientifically justified, expose MSCs to defined hypoxic, inflammatory, mechanical or three-dimensional culture conditions intended to modify their secretory profile.
Conditioning Phase
Maintain MSCs in a defined collection medium for a controlled period during which soluble and vesicular factors accumulate.
Medium Collection
Collect the conditioned medium using a documented procedure designed to maintain traceability and microbiological control.
Clarification
Remove intact cells, cellular debris and selected larger particles through controlled centrifugation, filtration or related methods.
Concentration or Fractionation
Concentrate the complete secretome or separate it into soluble, extracellular-vesicle-enriched or extracellular-vesicle-depleted fractions.
Formulation
Prepare the intended concentration, carrier, excipients, container and final presentation.
Characterisation and Release Review
Review composition, particle profile, contaminants, microbiological quality, stability and mechanism-relevant biological activity.
Molecular Composition
What may be present in the MSC secretome?
Composition must be established analytically and cannot be inferred solely from the term MSC.
Cytokines
Soluble proteins involved in immune regulation, inflammation and communication between cells.
Chemokines
Signalling molecules capable of influencing cellular migration, recruitment and tissue localisation.
Growth Factors
Factors associated with cellular survival, proliferation, vascular signalling and matrix biology.
Extracellular Vesicles
Heterogeneous membrane-enclosed particles carrying proteins, lipids, nucleic acids and metabolites.
Matrix-Regulating Proteins
Enzymes and regulatory proteins associated with extracellular-matrix production and remodelling.
Lipid Mediators
Vesicular and non-vesicular lipid components capable of participating in cellular signalling.
Metabolites
Products of cellular metabolism that may influence the biological profile of the preparation.
Nucleic Acids
Vesicle-associated RNA and other nucleic-acid material may form part of the secretome.
Residual Culture Components
Media proteins, supplements and process-related materials may remain unless specifically removed.
Potential Uses and Indications
Principal areas of scientific investigation
These categories describe research and development areas. They do not establish approved indications or proven therapeutic effectiveness.
Wound and Skin Biology
Research examines fibroblast activity, epithelial repair, angiogenic signalling, inflammation and extracellular-matrix production.
Musculoskeletal Medicine
Laboratory and preclinical research includes cartilage, tendon, bone, muscle and inflammatory joint environments.
Neurological Disorders
Studies evaluate neuroinflammatory, trophic, vascular and cytoprotective signalling rather than direct replacement of neurons.
Immune-Mediated Disorders
Research examines secretome interaction with macrophages, lymphocytes, dendritic cells and inflammatory signalling pathways.
Pulmonary Injury
Preclinical and early translational programmes investigate inflammatory, vascular and tissue-support pathways in lung injury.
Cardiovascular Research
Research includes angiogenesis, myocardial injury, vascular support and cellular-survival mechanisms.
Renal and Hepatic Injury
Experimental programmes examine inflammation, fibrosis, apoptosis and tissue-support signalling.
Ocular Applications
Secretome and conditioned-medium preparations are being studied for selected ocular-surface and tissue-repair applications.
Defined Cell-Free Biologics
The MSC secretome may serve as starting material for purified proteins, EV fractions or defined combinations of bioactive components.
Current Medical Use
Predominantly investigational—not routine standard care
Most MSC-secretome applications remain within laboratory research, preclinical development and early human investigation.
Limited clinical studies have evaluated secretome or conditioned-medium preparations in areas such as wound healing, dermatology, inflammatory disease and pulmonary injury. These studies do not establish that all MSC-secretome products are clinically effective or interchangeable.
Commercial availability at a clinic or through an online supplier does not independently demonstrate product identity, manufacturing consistency, regulatory authorisation or clinical efficacy.
Product Development Models
Individual preparation or standardised biologic product
The MSC secretome is not inherently patient-specific and is not automatically suitable for mass marketing. Its development model depends on the source cells, manufacturing system, intended use and regulatory pathway.
Patient-Linked Development
A secretome preparation may be linked to an individual patient when produced from autologous cells or under a defined named-patient protocol.
- Physician evaluation and clinical rationale
- Identified patient or assigned source cells
- Individual chain of identity and custody
- Batch-specific manufacturing record
- Product-specific analytical review
- Informed consent and clinical follow-up
Standardised Batch Manufacturing
Secretome products may also be developed from qualified allogeneic MSC banks using a controlled, repeatable manufacturing process.
- Qualified master and working cell banks
- Defined culture and conditioning parameters
- Batch-scale concentration and formulation
- Product specifications and release criteria
- Stability and distribution programme
- Applicable medicinal-product authorisation
Not automatically a mass-market therapy
A scalable manufacturing process may support broader distribution, but it does not by itself create an authorised medical product.
Commercial distribution requires appropriate product classification, manufacturing controls, safety evaluation, clinical evidence, labelling, traceability and jurisdiction-specific regulatory authorisation.
Characterisation and Quality Control
A secretome product must be analytically defined
Total protein concentration alone is insufficient to establish identity, quality, biological activity or clinical suitability.
Source-Cell Identity
Document tissue source, donor, immunophenotype, passage, viability and culture history.
Culture and Conditioning
Record medium, supplements, cell density, oxygen conditions, priming and collection duration.
Total Protein
Measure total protein as one compositional parameter without treating it as proof of potency.
Soluble-Factor Profile
Evaluate selected cytokines, chemokines, growth factors or enzymes relevant to the proposed mechanism.
Extracellular-Vesicle Profile
Assess particle concentration, size distribution, morphology and selected EV-associated components where relevant.
Purity and Residuals
Evaluate media proteins, supplements, aggregates and process-related materials.
Microbiological Quality
Assess sterility-related parameters, mycoplasma and endotoxin where applicable.
Functional Activity
Use a fit-for-purpose assay linked to the proposed immunological, trophic, vascular or tissue-support mechanism.
Stability
Establish the effects of formulation, storage, transport, holding time and freeze–thaw exposure.
Clinical and scientific qualification
MSC secretome, conditioned medium, purified exosomes, small extracellular vesicles and exosome-depleted conditioned medium describe related but distinct biological materials.
The MSC secretome is not “differentiated.” Source MSCs may be primed, preconditioned or lineage-directed, but the secretome itself is collected and processed.
A secretome preparation is not inherently sterile, standardised, patient-specific or suitable for clinical administration merely because it originates from MSCs.
Laboratory activity, animal research or preliminary human data do not independently establish safety or clinical effectiveness.
Potential applications in orthopaedics, neurology, immune-mediated disease, wound care, dermatology, pulmonary disease or organ injury remain investigational unless supported by product-specific clinical evidence and applicable authorisation.
The CELLMEX Approach
Defined source, controlled production and responsible translation
Define the Source Cells
Establish MSC identity, tissue origin, donor, passage, viability and culture history.
Control the Secretory Environment
Standardise medium, supplements, oxygen, cell density, priming conditions and collection period.
Define the Product Fraction
Distinguish complete secretome, conditioned medium, EV-enriched material and EV-depleted soluble fractions.
Characterise Composition
Evaluate relevant soluble proteins, vesicles, residual media components and process-related materials.
Establish Functional Activity
Use mechanism-relevant assays rather than relying solely on total protein, particle count or marketing terminology.
Match Development to Intended Use
Define whether the preparation is for research, patient-linked development or a standardised medicinal-product programme.
Selected Scientific References
MSC secretome biology and clinical translation
Trigo CM, et al. Mesenchymal stem cell secretome for regenerative medicine.
Review addressing soluble and vesicular secretome components and potential applications in respiratory, hepatic and neurological disorders.
View publicationFerreira JR, et al. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning.
Frontiers in Immunology. 2018;9:2837.
View publicationKumar P, et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine.
Cytokine & Growth Factor Reviews. 2019;46:1–9.
View publicationRanganath SH, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.
Cell Stem Cell. 2012.
View publicationTurlo AJ, et al. Mesenchymal Stromal Cell Secretome Is Affected by Tissue Source and Donor Age.
Study demonstrating source- and donor-associated differences in secretome protein composition.
View publicationSuhandi C, et al. Effectiveness of Mesenchymal Stem Cell Secretome on Wound Healing.
Systematic review of clinical parameters associated with wound-repair applications.
View publicationU.S. Food and Drug Administration. Consumer alert concerning regenerative-medicine products, including stem-cell and exosome products.
Regulatory and patient-safety information concerning unapproved regenerative-medicine products.
View FDA informationEuropean Medicines Agency. Stem-cell-based medicinal products scientific guideline.
Quality, nonclinical and clinical considerations relevant to medicinal products using stem cells as starting material.
View EMA guidance
Scientific Information
Request information concerning CELLMEX MSC-secretome research
Physicians, researchers and institutions may request information concerning MSC source-cell systems, secretome production, fractionation, characterisation, functional assays and scientific collaboration.